Similar to systemic ALCL, activation of the JAK-STAT3 pathway is a constant feature of BIA-ALCL, most commonly through mutations of STAT3 and/or JAK1 [16]. The gene discussed is STAT3; the disease is anaplastic large cell lymphoma.